# Seroba Life Sciences

Seroba Life Sciences is a Private Equity based in Dublin 2, Ireland.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Dublin 2, Ireland
- **Region:** Europe
- **Address:** Dublin 2, Ireland
- **Founded:** 2002
- **Assets under management:** Undisclosed
- **Website:** serobavc.com
- **LinkedIn:** https://www.linkedin.com/company/serobavc

## Regulatory record

- **Reports private funds:** No

## About

Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech. Complementary skill sets with deep investment and operational industry experience. Seroba helps entrepreneurs create and build world class businesses around extraordinary science.

## Sectors

- Biotech
- Medtech

## People

- Alan O'Connell — Partner
- Daniel O'Mahony — Partner
- Jennifer McMahon — Partner
- Bruno Montanari — Partner
- Catello Somma — Partner
- Maud Lazare — Investor relations, Partner
- Andrew Duignan — CFO, Partner
- Jeanne Bolger — Venture partner

## Questions

### Who runs investment decisions at Seroba?

Investment decisions are made by the partnership group, which includes Alan O'Connell, Daniel O'Mahony, Jennifer McMahon, Bruno Montanari, and Catello Somma. Venture partner Jeanne Bolger, formerly of Johnson & Johnson Innovation — JJDC, contributes deal origination and board-level guidance but is not listed as a managing partner. The group operates as a consensus-driven investment committee rather than through a single CIO structure.

### Does Seroba invest exclusively in Europe?

Yes. Seroba sources and leads investments across the European life sciences corridor, with named portfolio companies in Ireland, the UK, France, Germany, Italy, Belgium, and the Netherlands. While several portfolio companies seek FDA approval and have US operations, Seroba's investment mandate is rooted in European university spin-outs and early-stage ventures.

### What is Seroba's track record with exits?

The firm's partners have generated multiple trade-sale and acquisition exits to large pharma and medtech strategics. These include Fusion Pharmaceuticals (acquired by AstraZeneca), Prexton Therapeutics (acquired by Lundbeck), Veryan Medical (acquired by Otsuka Medical), Covagen (acquired by Johnson & Johnson), and Apica Cardiovascular (acquired by Thoratec). The exit timeline spans from 2014 through the AstraZeneca acquisition of Fusion.

### How is Seroba's partnership structured differently from other European life sciences VCs?

Several partners have been with the firm since the early 2000s, including Alan O'Connell (2003) and Daniel O'Mahony (2009), which is unusually stable for a European venture firm. The group also blends operating backgrounds from corporate venture (J&J, Elan), investment banking (Deutsche Bank, Merrill Lynch), and technology transfer offices, giving it both syndicate networks and hands-on development expertise.

## Related profiles

- [Series Ventures](https://altss.com/profile/series-ventures)
- [Sero Capital](https://altss.com/profile/sero-capital)

---

Last updated: 2026-08-11T15:08:04.536Z

Canonical page: https://altss.com/profile/seroba-life-sciences

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology